Allstate Corporation’s Sarepta Therapeutics SRPT Stock Holding History

Allstate Corporation’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$444K	Sell	24,708 -10,547	-30%	-$199K	﹤0.01%	1078
2026 Q1	$767K	Buy	+35,255	New	+$682K	0.01%	892
2021 Q1	–	Sell	-2,585	Closed	-$441K	–	741
2020 Q4	$441K	Buy	2,585 +118	+5%	+$17.5K	0.01%	546
2020 Q3	$346K	Hold	2,467	–	–	0.01%	534
2020 Q2	$396K	Sell	2,467 -781	-24%	-$106K	0.01%	511
2020 Q1	$318K	Buy	3,248 +1,342	+70%	+$153K	0.01%	482
2019 Q4	$246K	Buy	+1,906	New	+$192K	﹤0.01%	580
2019 Q3	–	Sell	-6,964	Closed	-$1.06M	–	533
2019 Q2	$1.06M	Buy	+6,964	New	+$846K	0.02%	381

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Allstate Corporation's SRPT Position: Q2 2026 in Review

Allstate Corporation reduced its Sarepta Therapeutics (SRPT) stake by 30% in Q2 2026, selling an estimated $199K and leaving 24,708 shares worth $444K. The position accounts for ﹤0.01% of the portfolio, ranked #1078.

Allstate Corporation first reported a position in SRPT in Q2 2019 and has held it in 8 quarters since. The position peaked at $1.06M in Q2 2019. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Allstate Corporation held 24,708 shares of Sarepta Therapeutics worth $444K as of Q2 2026.
Allstate Corporation sold 10,547 Sarepta Therapeutics shares in Q2 2026, an estimated $199K.
Sarepta Therapeutics made up ﹤0.01% of Allstate Corporation's portfolio in Q2 2026, its #1078 holding.
Allstate Corporation first reported a position in Sarepta Therapeutics in Q2 2019 and has held it in 8 quarters since.
Allstate Corporation's Sarepta Therapeutics position peaked at $1.06M in Q2 2019.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.